{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:13:00Z","timestamp":1788541980988,"version":"build-2803163510"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Despite widespread use, concerns have emerged regarding the increased risks of digestive system cancers associated with use of proton pump inhibitors (PPIs). Moreover, ranitidine was recalled from the market in some countries due to its potential carcinogenicity, which also has raised concern about cancer risk in association with use of histamine-2 receptor antagonists (H2RAs). We comprehensively explored the potential risks of various cancers associated with use of PPIs and H2RAs by analyzing the FDA Adverse Event Reporting System (FAERS), aiming to offer real-world evidence for the safe and rational use of acid suppressive agents. OpenVigil 2.1 was utilized to query the FAERS database. Cancer related adverse events (AEs) included Preferred Terms (PTs) of malignant neoplasms among all cancer sites. Disproportionality analysis was performed, and a positive signal indicated a statistical association between cancer related AEs and drugs. Most PPIs had more cancer related PTs with positive signals than H2RAs (except ranitidine), but had fewer cancer related PTs with positive signals than ranitidine. Forty-three cancer related PTs exhibited positive signals for more than one PPIs, and the major cancer sites of these PTs were gastric, lung, lymphomas, pancreatic, oesophageal, intestinal, upper respiratory tract, renal, soft tissue, and so on. Besides, only two cancer related PTs exhibited positive signals for more than one H2RAs (except ranitidine). Our study suggests that PPIs may be associated with more cancer related AEs than H2RAs (except ranitidine), but may be associated with fewer cancer related AEs than ranitidine. Except for digestive system cancers, use of PPIs may also be associated with increased risks of multiple non-digestive system cancers. According to our findings, H2RAs (except ranitidine) may be safer than PPIs regarding cancer risk, and the priority use of PPIs for acid suppression therapy may not be appropriate.<\/jats:p>","DOI":"10.1371\/journal.pone.0329385","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T17:32:06Z","timestamp":1755019926000},"page":"e0329385","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cancer related adverse events associated with use of proton pump inhibitors and histamine-2 receptor antagonists: A real-world analysis using the FDA adverse event reporting system"],"prefix":"10.1371","volume":"20","author":[{"given":"Bowen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheyun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiubi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xida","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7374-7226","authenticated-orcid":true,"given":"Xue-Feng","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"issue":"12","key":"pone.0329385.ref001","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-041529","article-title":"Trends in acid suppressant drug prescriptions in primary care in the UK: a population-based cross-sectional study","volume":"10","author":"D Abrahami","year":"2020","journal-title":"BMJ Open"},{"issue":"1","key":"pone.0329385.ref002","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/bjc.2011.511","article-title":"Proton pump inhibitors and histamine-2-receptor antagonists and pancreatic cancer risk: a nested case-control study","volume":"106","author":"MC Bradley","year":"2012","journal-title":"Br J Cancer"},{"issue":"1","key":"pone.0329385.ref003","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/j.gastro.2017.04.047","article-title":"Complications of proton pump inhibitor therapy","volume":"153","author":"MF Vaezi","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"pone.0329385.ref004","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/gutjnl-2021-325097","article-title":"Proton pump inhibitors and risk of gastric cancer: population-based cohort study","volume":"71","author":"D Abrahami","year":"2021","journal-title":"Gut"},{"issue":"1","key":"pone.0329385.ref005","doi-asserted-by":"crossref","first-page":"101397","DOI":"10.1016\/j.clinre.2020.02.017","article-title":"Association between use of proton pump inhibitors and colorectal cancer: a nationwide population-based study","volume":"45","author":"W-Y Lei","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"4","key":"pone.0329385.ref006","article-title":"Proton pump inhibitor use is associated with risk of pancreatic cancer: a nested case-control study","volume":"16","author":"Y-C Peng","year":"2018","journal-title":"Dose Response"},{"key":"pone.0329385.ref007","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.canep.2018.02.004","article-title":"Maintenance proton pump inhibition therapy and risk of oesophageal cancer","volume":"53","author":"N Brusselaers","year":"2018","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"pone.0329385.ref008","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/apt.14796","article-title":"Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies","volume":"48","author":"KT Tran","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0329385.ref009","article-title":"FDA recalls ranitidine medicines over potential cancer causing impurity","volume":"367","author":"E Mahase","year":"2019","journal-title":"BMJ"},{"issue":"3","key":"pone.0329385.ref010","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s40264-020-01024-0","article-title":"Risk of cancer in association with ranitidine and nizatidine vs other H2 blockers: analysis of the Japan Medical Data Center Claims Database 2005-2018","volume":"44","author":"M Iwagami","year":"2021","journal-title":"Drug Saf"},{"issue":"5","key":"pone.0329385.ref011","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1053\/j.gastro.2020.12.037","article-title":"Ranitidine use and cancer risk: results from UK Biobank","volume":"160","author":"ED Kantor","year":"2021","journal-title":"Gastroenterology"},{"issue":"1","key":"pone.0329385.ref012","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/cancers13010024","article-title":"The association between ranitidine use and gastrointestinal cancers","volume":"13","author":"G McGwin","year":"2020","journal-title":"Cancers"},{"issue":"8","key":"pone.0329385.ref013","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.14309\/ajg.0000000000001310","article-title":"Exposure to ranitidine and risk of bladder cancer: a nested case-control study","volume":"116","author":"CR Cardwell","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"pone.0329385.ref014","unstructured":"FDA Adverse Event Reporting System (FAERS) Quarterly Data Extract Files. 2023. https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html"},{"issue":"2","key":"pone.0329385.ref015","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/jamia\/ocv063","article-title":"Use of data mining at the Food and Drug Administration","volume":"23","author":"HJ Duggirala","year":"2016","journal-title":"J Am Med Inform Assoc"},{"key":"pone.0329385.ref016","doi-asserted-by":"crossref","first-page":"1045561","DOI":"10.3389\/fphar.2022.1045561","article-title":"Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: a real-world analysis using the FDA adverse event reporting system","volume":"13","author":"X-F Jiao","year":"2023","journal-title":"Front Pharmacol"},{"issue":"4","key":"pone.0329385.ref017","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/17425255.2023.2219390","article-title":"A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database","volume":"19","author":"H Yang","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"pone.0329385.ref018","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17425255.2023.2235267","article-title":"A real-world data analysis of acetylsalicylic acid in FDA Adverse Event Reporting System (FAERS) database","volume":"19","author":"B Zhao","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"pone.0329385.ref019","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/andr.13533","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system events for sildenafil","volume":"12","author":"Y Wang","year":"2024","journal-title":"Andrology"},{"key":"pone.0329385.ref020","doi-asserted-by":"crossref","first-page":"1333662","DOI":"10.3389\/fphar.2024.1333662","article-title":"A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system","volume":"15","author":"B Zhao","year":"2024","journal-title":"Front Pharmacol"},{"key":"pone.0329385.ref021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2024\/5132916","article-title":"Vitreoretinal traction syndrome, nitrituria and human epidermal growth factor receptor negative might occur in the aromatase-inhibitor anastrozole treatment","volume":"2024","author":"J Li","year":"2024","journal-title":"Int J Clin Pract"},{"issue":"11","key":"pone.0329385.ref022","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1080\/14740338.2024.2410436","article-title":"A real-world pharmacovigilance study using disproportionality analysis of United States Food and Drug Administration Adverse Event Reporting System events for vinca alkaloids: comparing vinorelbine and Vincristine","volume":"23","author":"C Zhong","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"pone.0329385.ref023","unstructured":"FDA Adverse Event Reporting System (FAERS): Latest Quarterly Data Files. 2023. https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files"},{"issue":"2","key":"pone.0329385.ref024","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nbt.2113","article-title":"OpenVigil--free eyeballs on AERS pharmacovigilance data","volume":"30","author":"R B\u00f6hm","year":"2012","journal-title":"Nat Biotechnol"},{"key":"pone.0329385.ref025","unstructured":"B\u00f6hm R, Herdegen T. Using the OpenVigil 2 pharmacovigilance tool for guidance for clinical decisions involving newly occurring adverse events. GPTS Congress 2016, Poster #408. 2023. http:\/\/openvigil.sourceforge.net\/doc\/2016-poster-dgpt-openvigil-decision-making-6-no-pix.pdf"},{"key":"pone.0329385.ref026","unstructured":"MedDRA. Introductory Guide MedDRA Version 22.1. 2022. https:\/\/www.meddra.org\/sites\/default\/files\/guidance\/file\/000354_intguide_22.1.pdf"},{"issue":"6","key":"pone.0329385.ref027","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"SJ Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"pone.0329385.ref028","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/apm.12380","article-title":"Hypergastrinemia is associated with adenocarcinomas in the gastric corpus and shorter patient survival","volume":"123","author":"R Fossmark","year":"2015","journal-title":"APMIS"},{"key":"pone.0329385.ref029","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/5584_2019_366","article-title":"Helicobacter pylori infection, the gastric microbiome and gastric cancer","volume":"1149","author":"J Pereira-Marques","year":"2019","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"pone.0329385.ref030","doi-asserted-by":"crossref","first-page":"188309","DOI":"10.1016\/j.bbcan.2019.07.004","article-title":"Microbial carcinogenesis: Lactic acid bacteria in gastric cancer","volume":"1872","author":"K Vinasco","year":"2019","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"11","key":"pone.0329385.ref031","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/COC.0000000000000949","article-title":"Proton pump inhibitors and cancer risk: an umbrella review and meta-analysis of observational studies","volume":"45","author":"M-L Zhang","year":"2022","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"pone.0329385.ref032","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5009\/gnl15502","article-title":"25 Years of Proton Pump Inhibitors: A Comprehensive Review","volume":"11","author":"DS Strand","year":"2017","journal-title":"Gut Liver"},{"issue":"3","key":"pone.0329385.ref033","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/gastro\/gov004","article-title":"Hypergastrinemia","volume":"3","author":"S Dacha","year":"2015","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"3","key":"pone.0329385.ref034","article-title":"Adverse drug reaction signal detection methods in spontaneous reporting system: a systematic review","volume":"33","author":"X-F Jiao","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0329385","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T17:32:13Z","timestamp":1755019933000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0329385"}},"subtitle":[],"editor":[{"given":"Taj Muhammad Jahangir","family":"Khuhawar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0329385","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}